- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | XOMA Royalty to acquire Generation Bio | 1 | Seeking Alpha | ||
| Mo | Generation Bio Co.; XOMA Royalty Corporation: XOMA Royalty Enters into Agreement to Acquire Generation Bio | 1 | GlobeNewswire (USA) | ||
| Fr | XOMA stock maintains Buy rating at Benchmark despite partner's trial setback | 1 | Investing.com | ||
| Do | Why Is XOMA Royalty Stock Sinking Thursday? | 3 | Benzinga.com | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| Do | XOMA stock price target lowered to $97 by H.C. Wainwright | 6 | Investing.com | ||
| Do | Leerink Partners lowers XOMA stock price target on RZ358 trial failure | 2 | Investing.com | ||
| Do | XOMA: Leerink Partners senkt Kursziel nach gescheiterter RZ358-Studie | 17 | Investing.com Deutsch | ||
| Do | Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug | 16 | Investor's Business Daily | ||
| 09.12. | Lucid Capital Markets initiates coverage on XOMA stock with Buy rating | 3 | Investing.com | ||
| 05.12. | XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share | 8 | Investing.com | ||
| 05.12. | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc | 284 | GlobeNewswire (Europe) | EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously... ► Artikel lesen | |
| 05.12. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 05.12. | XOMA Royalty completes acquisition of Mural Oncology | 1 | Investing.com | ||
| 05.12. | XOMA Royalty schließt Übernahme von Mural Oncology ab | 2 | Investing.com Deutsch | ||
| 03.12. | Irish court approves XOMA Royalty's acquisition of Mural Oncology | 3 | Investing.com | ||
| 27.11. | Spotlight Stock Market: Market Notice 213/25 - Correction: Market Notice 209/25 - Information regarding the rights issue from Xoma AB | 2 | Cision News | ||
| 26.11. | XOMA legt Übernahmepreis für Mural Oncology auf 2,035 US-Dollar pro Aktie fest | 3 | Investing.com Deutsch | ||
| 26.11. | XOMA Royalty to acquire Mural Oncology for $2.035 per share | 4 | Investing.com | ||
| 26.11. | Mural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty | 216 | GlobeNewswire (Europe) | WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between... ► Artikel lesen | |
| 21.11. | XOMA Royalty schließt Übernahme von LAVA Therapeutics ab | 2 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
96 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today | ||
| APOGEE THERAPEUTICS | 76,81 | -0,35 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| ADMA BIOLOGICS | 19,730 | -0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,335 | -0,03 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DISC MEDICINE | 92,00 | +0,16 % | H.C. Wainwright reiterates Buy rating on Disc Medicine stock | ||
| VERA THERAPEUTICS | 49,170 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,300 | 0,00 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 19,010 | -0,31 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| RADIOPHARM THERANOSTICS | 10,630 | 0,00 % | Radiopharm (RADX) Sees Slight Pessimism From Analysts | ||
| KYVERNA THERAPEUTICS | 10,810 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 35,840 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| PRAXIS PRECISION MEDICINES | 276,42 | +2,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 79,95 | +0,19 % | BioNTech-Aktie: Die Hoffnung ist zurück | Die Mainzer stärken ihre eigene Position im Markt, neue Daten dürften Aufwärtsdruck liefern. Mit der Übernahme von Curevac, die nach Erreichen der Mindestannahmeschwelle Ende letzter Woche noch in diesem... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,080 | -5,84 % | LENZ Therapeutics, Inc. - 8-K, Current Report |
Das Unternehmen XOMA CORPORATION PREF kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 22,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.